CFTR Modulators for DeltaF508 Protein Folding and Trafficking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ABC transporter-mediated diseases, particularly those affecting CFTR function, are limited in efficacy and specificity, especially for mutations like ΔF508-CFTR, which impede proper protein folding and trafficking, leading to severe conditions such as cystic fibrosis and related disorders.
Innovation Solution
Development of compounds with a specific formula that modulate ABC transporter activity, including CFTR, to enhance protein folding, trafficking, and function, thereby addressing the underlying defects in diseases like cystic fibrosis and other protein folding disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for ABC transporter-mediated diseases are used, then treatment coverage is provided, but efficacy and specificity are limited
Solution Approach 1:
The patent develops compounds with specific molecular structures (formula I and II) that are designed to interact with specific mutation sites on CFTR proteins, particularly addressing the ΔF508 mutation. This localized targeting approach allows the treatment to be highly specific to certain mutations while maintaining efficacy, resolving the contradiction between broad treatment coverage and mutation-specific effectiveness.
Solution Approach 2:
The invention employs compounds that induce conformational changes in the CFTR protein structure, altering its folding and trafficking parameters. By changing the physical-chemical parameters of the protein (folding state, membrane trafficking efficiency), the treatment achieves both efficacy improvement and enhanced specificity for mutations that affect these parameters, such as ΔF508-CFTR.
2Stability of the object's composition
If compounds modulate CFTR activity to enhance protein folding and trafficking, then protein stability and function improve, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent uses small molecule compounds as intermediaries that bind to CFTR proteins and facilitate proper folding and trafficking. These intermediary molecules act as molecular chaperones, simplifying the therapeutic approach by using a single agent to address multiple aspects of protein misfolding and trafficking defects, rather than requiring complex combination therapies.
Solution Approach 2:
The compounds described in the patent enable the CFTR protein to self-correct its folding and trafficking defects. By providing the right molecular cues, the treatment allows the protein to undergo spontaneous conformational changes and reach its functional state without requiring external cellular machinery or complex biological pathways, thus improving stability while maintaining relative simplicity.
Data Source
AI summary
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.